伯基特淋巴瘤 (BL) 与 Epstein-Barr 病毒 (EBV) 密切相关，尤其是在撒哈拉以南非洲地区。虽然 BL 和 EBV 之间的关系已有充分记录，但抗 EBV 适应性免疫反应（尤其是撒哈拉以南非洲病例）与病程之间的关系尚未得到充分研究。本文报道的来自 EBV 阳性乌干达 BL 肿瘤样本的 T 细胞受体 (TCR) 互补决定区 3 (CDR3) 序列的分析揭示了抗 EBV CDR3 的存在与总体生存概率提高之间的相关性。此外，化学互补性评估表明，在 BL 肿瘤样本中检测到抗 EBV CDR3 AA 序列匹配的情况下，TCR CDR3 和 EBV 表位具有更高的互补性。总体而言，本文报告的结果提出了 EBV 靶向免疫治疗是否会带来更好的 BL 结果的问题？© 2024 UICC。

Burkitt lymphoma (BL) has a tight association with Epstein-Barr virus (EBV), especially in sub-Saharan Africa. While the relationship between BL and EBV is well documented, the relationship between the anti-EBV adaptive immune response, particularly in sub-Saharan African cases, and disease course, has not been substantially investigated. An analysis of T-cell receptor (TCR) complementarity determining region-3 (CDR3) sequences, reported here, from EBV-positive, Ugandan BL tumor samples revealed a correlation between the presence of anti-EBV CDR3s and improved overall survival probabilities. Furthermore, chemical complementarity assessments demonstrated higher complementarity for TCR CDR3s and EBV epitopes in the cases where there had been a detection of the anti-EBV CDR3 AA sequence matches in the BL tumor samples. Overall, the results reported here raise the question of whether EBV targeted immunotherapy would lead to better BL outcomes?© 2024 UICC.